A phase II clinical trial in relapsed/refractory DLBCL evaluating the combination of the oral HDAC inhibitor palbociclib (40 mg three times weekly) with the oral mTOR inhibitor Everolimus showed an objective response rate of 25%. This evidence concerns the gene HDAC9 and diffuse large B-cell lymphoma.